FAK-Activated Mucosal Healing Promotes Resistance to Reinjury
Cells · 2025
DOI: 10.3390/cells15010016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sema Oncel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of North Dakota School of Medicine & Health Sciences, Grand Forks, ND 58203, USA. Hauptthemen laut MEDLINE: Wound Healing, Intestinal Mucosa, Focal Adhesion Protein-Tyrosine Kinases, Focal Adhesion Kinase 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Gastrointestinal (GI) mucosal injury is a frequent complication of long-term nonsteroidal anti-inflammatory drug (NSAID) use. Effective mucosal healing requires coordinated epithelial migration, proliferation, and angiogenesis, which may be influenced by focal adhesion kinase (FAK). This study aimed to determine whether our newly developed FAK activators promote intestinal mucosal healing by enhancing angiogenesis and whether FAK activation increases resistance to reinjury.
Methods
Ischemic jejunal ulcers were induced in C57BL/6 mice. After 24 h, mice received intraperitoneal injections of the FAK activator ZINC40099027 (ZN27, 900 µg/kg every 6 h) or vehicle for 2, 4, or 14 days. Ulcer areas were quantified, and liver and kidney function were assessed. Ulcer and adjacent tissues were analyzed by immunofluorescence staining for angiogenesis and proliferation markers. In vitro, human umbilical vein endothelial cells (HUVECs) were treated with ZN27 to evaluate proliferation, migration, angiogenesis, and intracellular signaling. In a reinjury model, male C57BL/6J mice received continuous infusion of the FAK activator M64HCl (25 mg/kg/day) or vehicle for 7 days, with a single subcutaneous injection of indomethacin (10 mg/kg) on day 1 to induce GI injury. Fourteen days after the first dose of indomethacin, the mice received a second indomethacin challenge, and one day later, total ulcer areas in the pyloric opening and small intestine were quantified.
Results
Ulcer areas were significantly smaller in ZN27-treated mice compared with vehicle-treated controls at 3 and 5 days, accompanied by increased expression of angiogenesis and proliferation markers. In vitro, ZN27 enhanced HUVEC migration via FAK activation in an ERK1/2-dependent manner and increased the number of angiogenic sprouts. In the reinjury model, treatment with M64HCl during the initial indomethacin-induced injury resulted in significantly smaller ulcer areas in both the pyloric opening and small intestine after the second indomethacin challenge compared with controls.
Conclusions
FAK activation accelerates ischemic ulcer healing, in part by enhancing angiogenesis. Moreover, FAK activation during an initial injury reduces susceptibility to recurrent NSAID-induced intestinal injury, perhaps because it promotes initial higher-quality ulcer repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of North Dakota School of Medicine & Health Sciences, Grand Forks, ND 58203, USA.
- Department of Biomedical Sciences, Northeast Ohio Medical University College of Medicine, Rootstown, OH 44272, USA.
- Department of Surgery, University of North Dakota School of Medicine & Health Sciences, Grand Forks, ND 58203, USA.
- Department of Pathology, University of North Dakota School of Medicine & Health Sciences, Grand Forks, ND 58203, USA.
- Institute for Therapeutics Discovery and Development and Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55414, USA.
ORCID-Profile: Sema Oncel, Guiming Liu, Louis Kwantwi, Emilie E Vomhof-DeKrey, Ricardo Gallardo-Macias, Vadim J Gurvich, Marc D Basson
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Oncel, S., Liu, G., Kwantwi, L., Vomhof-DeKrey, E. E., Gallardo-Macias, R., Gurvich, V. J., & Basson, M. D. (2025). FAK-Activated Mucosal Healing Promotes Resistance to Reinjury. Cells. https://doi.org/10.3390/cells15010016
Vancouver
Oncel S, Liu G, Kwantwi L, Vomhof-DeKrey EE, Gallardo-Macias R, Gurvich VJ, et al. FAK-Activated Mucosal Healing Promotes Resistance to Reinjury. Cells. 2025. doi:10.3390/cells15010016
BibTeX
@article{Oncel2025,
author = {Oncel, Sema and Liu, Guiming and Kwantwi, Louis and Vomhof-DeKrey, Emilie E and Gallardo-Macias, Ricardo and Gurvich, Vadim J and Basson, Marc D},
title = {FAK-Activated Mucosal Healing Promotes Resistance to Reinjury},
journal = {Cells},
year = {2025},
doi = {10.3390/cells15010016}
}
EUVIMED